| Stereochemistry | ABSOLUTE |
| Molecular Formula | C65H101N17O16S |
| Molecular Weight | 1408.667 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@@]([H])(NC1=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CSC(=N4)[C@@H](N)[C@@H](C)CC)C(C)C
InChI
InChIKey=KPXXOQKPVWZIEU-QTFUODODSA-N
InChI=1S/C65H101N17O16S/c1-9-35(7)51(68)65-80-47(31-99-65)62(96)75-42(25-33(3)4)58(92)73-41(21-22-49(84)85)57(91)81-52(34(5)6)63(97)74-39-19-14-15-24-70-54(88)45(28-48(67)83)77-61(95)46(29-50(86)87)78-60(94)44(27-38-30-69-32-71-38)76-59(93)43(26-37-17-12-11-13-18-37)79-64(98)53(36(8)10-2)82-56(90)40(20-16-23-66)72-55(39)89/h11-13,17-18,30,32-36,39-47,51-53H,9-10,14-16,19-29,31,66,68H2,1-8H3,(H2,67,83)(H,69,71)(H,70,88)(H,72,89)(H,73,92)(H,74,97)(H,75,96)(H,76,93)(H,77,95)(H,78,94)(H,79,98)(H,81,91)(H,82,90)(H,84,85)(H,86,87)/t35-,36-,39-,40+,41+,42-,43+,44-,45-,46+,47-,51-,52-,53-/m0/s1
| Molecular Formula | C65H101N17O16S |
| Molecular Weight | 1408.667 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
Bacitracin B3 is one of major components of bacitracin, a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Bacitracin exerts pronounced antibacterial action in vitro against a variety of gram-positive and a few gram-negative organisms. However, among systemic diseases, only staphylococcal infections qualify for consideration of bacitracin therapy. Bacitracin A, B1, B2 and B3, short bacitracins A and B represent about 96% of the total microbiological activity in pharmaceutical formulations
Originator
Approval Year
PubMed
Patents
Sample Use Guides
As a polypeptide, toxic, and difficult to use chemical, bacitracin doesn't work well orally, however is very effective topically. Insulin (1 mgЖmL)1) was incubated in 100 mm potassium phosphate and 1 mm EDTA (pH 7.4), in the presence of 10 mkg/mL PDI and varying amounts of bacitracin analog (Bacitracin B) at room temperature. The reaction was initiated after 10 min by the addition of 0.1 mm dithiothreitol, and the increase in turbidity was monitored at 562 nm on an Elx808 Ultra Microplate Reader (Bio-Tex Instruments, Winooski, VT, USA) over 100 min. Dose–response curves were generated, with expression of PDI activity as absorbance at 100 min as a percentage of the absorbance of the control reaction containing no inhibitor, after subtraction of the absorbance of the uncatalyzed reaction containing no PDI.
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 2 of 2 entries
